The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Jefferies analyst Stephen Barker maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on January 19 and set a price ...

AstraZeneca and Daiichi Sankyo won U.S. approval for a novel breast ... another new cancer medicine co-developed by the companies, Enhertu. The approval is the first in the U.S. for Datroway ...

Enhertu's objective response rate was significantly higher than chemotherapy, with notable complete and partial response rates. Enhertu carries a boxed warning for embryo-fetal toxicity and ...

New approval brings the medicine to an earlier treatment setting and a broader patient population.

Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners' Datroway for a related type of breast ...

Daiichi Sankyo's stock has dropped 25% since my last update due to disappointing clinical data from Dato-DXd studies, but upcoming read-outs in 2025 could drive a meaningful rebound. Dato-DXd ...

The drug, developed in partnership with Japan-based Daiichi Sankyo, will be marketed under ... the first being the blockbuster Enhertu. Per the terms of the partnership, both companies are jointly ...

TOKYO & BASKING RIDGE, N.J., January 13, 2025--(BUSINESS WIRE)--Daiichi Sankyo Company ... of advanced solid tumors including non-small cell lung, breast, urothelial, ovarian, biliary tract ...